Wefox has secured funding of EUR 151 m, consisting of a EUR 76 m capital raise primarily from Chrysalis and other existing investors and a refinancing of an existing credit facility with EUR 75 m from Searchlight Capital
Tags :Walder Wyss
Walder Wyss advised biotech company Alvotech throughout its acquisition of the Ivers-Lee Group (Ivers-Lee). The parties Luxembourg-based Alvotech is a globally active biotech company specialising in the development and manufacture of biosimilar medicines for patients
Walder Wyss advised UBS Switzerland in connection with its role as mandated lead arranger, coordinator, agent and security agent within a credit facilities agreement for QR Group. On that same transaction, Zürcher Kantonalbank served
Walder Wyss advised Raiffeisen Switzerland Cooperative in connection with its role as original lender, coordinator and security agent in the financing of Halphamicron Holding, leading to the acquisition of Vasconi SA, TS Décolletage SA
Swiss clinical-stage radiopharmaceutical company Nuclidium completed a Series B financing round, raising CHF 79 million (EUR 84 million). Vischer advised Nuclidium throughout the operation, while Walder Wyss advised Angelini Ventures, Kurma Partners and Wellington Partners, in connection
Walder Wyss advised Energie 360° on its acquisition of Move Mobility from VISCHER acted as legal counsel to Primeo Energie, Groupe E and ewb. In connection with the deal Vischer advised the selling parties .Headquartered in
Walder Wyss advised CPM Partners’ founders and shareholders on the sale of a majority stake to funds advised by investment firm Deutsche Private Equity. CPM Partners is a consulting and technology services company specialised in
Software and cloud solutions specialist SoftwareOne through completion of its recommended voluntary share and cash offer for all issued shares in Crayon. the deal Following fulfilment of the last closing condition, SoftwareOne has settled the
Walder Wyss advised Boostbar, a Switzerland- and UK-based company specialising in unattended retail technology, on its EUR 16 million Series B equity financing round. Direttissima Growth Partners led the round in question, with participation from Capmont
Walder Wyss advised the investors in Mosanna Therapeutics’ Series A financing round EQT Life Sciences and Pivotal bioVenture Partners led the round in question, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning
